Researchers at Mount Sinai have developed a novel approach to cancer immunotherapy, injecting immune stimulants directly into a tumor to teach the immune system to destroy it and other tumor cells throughout the body.
The “in situ vaccination” worked so well in patients with advanced-stage lymphoma that it is also undergoing trials in breast and head and neck cancer patients, according to a study published in Nature Medicine in April.
The treatment consists of administering a series of immune stimulants directly into one tumor site. The first stimulant recruits important immune cells called dendritic cells that act like generals of the immune army. The second stimulant activatesthe dendritic cells, which then instruct T cells, the immune system’s soldiers, to kill cancer cells and spare non-cancer cells. This immune army learns to recognize features of the tumor cells so it can seek them out and destroy them throughout the body, essentially turning the tumor into a cancer vaccine factory.
“The in situ vaccine approach has broad implications for multiple types of cancer,” said lead author Joshua Brody, MD, Director of the Lymphoma Immunotherapy Program at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai. “This method could also increase the success of other immunotherapies such as checkpoint blockade.”
After testing the lymphoma vaccine in the lab, it was tested in 11 patients in a clinical trial. Some patients had full remission from months to years. In lab tests in mice, the vaccine drastically increased the success of checkpoint blockade immunotherapy, the type of immunotherapy responsible for the complete remission of former President Jimmy Carter’s cancer and the focus of the 2018 Nobel Prize in Medicine.
A clinical trial for lymphoma, breast, and head and neck cancer patients opened in March to test the vaccine with checkpoint blockade drugs. Because the combined immune therapy was at least three times more powerful than either checkpoint blockade or the vaccine by themselves, researchers are extremely optimistic about how effective this may be in patients in this new trial. The in situ vaccine is also being tested in the lab in liver and ovarian cancer.
Learn more: Mount Sinai Researchers Develop Treatment That Turns Tumors Into Cancer Vaccine Factories
The Latest on: Cancer immunotherapy
[google_news title=”” keyword=”cancer immunotherapy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Cancer immunotherapy
- The portable 3D bioprinter joining the fight against canceron March 31, 2023 at 8:46 am
Details of their approach are reported in the journal Biofabrication. Immunotherapy is a form of cancer treatment that uses the body's immune system to identify and fight cancer cells. When it comes ...
- Lab Notes: Imvax advances brain cancer treatment; Wistar identifies promising compound for HIV patientson March 31, 2023 at 8:07 am
Here is the roundup: The Philadelphia immunotherapy company said it dosed its first patient in a Phase 2 clinical trial for IGV-001, its experimental therapy for a type of brain cancer known as ...
- A cancer-wide analysis finds cancer-wide targets for tumor reductionon March 31, 2023 at 8:00 am
Researchers at the Washington University School of Medicine, St. Louis, have discovered a potential new target for cancer immunotherapy in transposable elements (TEs), short segments of DNA that can ...
- Innovative Cancer Immunotherapy Wins 2023 Falcons' Fortunes Pitch Competitionon March 31, 2023 at 7:02 am
DTPx is developing a novel immunotherapy targeting hibernating cells to prevent relapse in colorectal cancer patients, which intends to alleviate pain and ease the burden on the healthcare system.
- ImmuneOnco Banks On Cutting-edge Cancer Drugs To Attract IPO Cashon March 31, 2023 at 6:23 am
ImmuneOnco’s main product pipeline is a cancer drug targeting a promising protein pathway, the first such drug to enter clinical tests in China, with more intensive trials due in the fourth quarter ...
- Study shows how neutrophils play a key role in cancer immunotherapy successon March 30, 2023 at 9:43 pm
Cancer immunotherapies that recruit a patient's own immune system to destroy tumors have transformed the treatment of many types of cancer. Yet these therapies do not elicit universally good treatment ...
- 2nd Annual Adenosine-Pathway Targeted Cancer Immunotherapy Summiton March 30, 2023 at 10:46 am
Exciting results are expected this year, from multiple mid and late stage clinical trials and involving a broad array of adenosine drugs including CD73, CD39 and A2AR! To ensure the community can ...
- Immunotherapy for NSCLC Safe in Elderly Patients, but More Research Neededon March 30, 2023 at 5:56 am
A review based on an expert panel discussion highlights a need for the inclusion of older patients in studies of immune checkpoint inhibitors for the first-line treatment of advanced non–small cell ...
- How a Lowly Immune Cell Helps the Immune System Fight Canceron March 30, 2023 at 5:01 am
A new study shows that immune cells called neutrophils can affect the success of immunotherapy in treating cancer. Neutrophil type is critical to treatment response because some neutrophils promote ...
- Novel immunotherapy delivery approach safe and beneficial for some melanoma patients with leptomeningeal diseaseon March 29, 2023 at 5:00 pm
A novel approach to administer intrathecal (IT) immunotherapy (directly into the spinal fluid) and intravenous (IV) immunotherapy was safe and improved survival in a subset of patients with ...
via Bing News